Abbott's 32% Slide Has Pushed ABT Below Fair Value-But Is the Discount Real or Just Fear?

Valuation suggests Abbott may be priced for panic, not business failure

Abbott looks damaged mainly because fear has drowned out fundamentals over the past year. The stock is down 32.0% over the past year, and at $112 it remains only modestly above its $105 52-week low. After a selloff like that, investors often stop focusing on cash flows and start hunting for reasons the decline is justified. That is where both the opportunity and the risk sit.

Several valuation snapshots suggest Abbott may be hated more than broken. One source points to an intrinsic value of 114.60 Intrinsic Value. Another estimates the shares trade at about a 39.5% discount to fair value. None of that settles the case for Abbott, but it does suggest price has fallen faster than the underlying business.

The real debate is whether the market is spotting near-term pain investors are missing, or simply still anchoring to the worst headlines. The risks are real: litigation in the nutrition business and FDA-related sentiment around glucose readings can keep shares depressed even if core operations remain healthy.

Abbott's operating engines still look intact

Medical Devices is still expanding

What matters now is not whether the chart looks bruised, but whether Abbott still has the growth drivers that justified a premium valuation before.

The clearest signal is that its largest segment is still growing. In the fourth quarter of 2025, the Medical Devices segment grew 10.5%, while annual continuous glucose monitoring sales topped $7.5 billion. Those are not the results of a business losing strategic traction.

Abbott also appears to have more than one growth thread. Commentary around the company increasingly describes it as a multi-engine business, with Rhythm Management, Structural Heart, and electrophysiology advancing alongside the diabetes platform. Even electrophysiology showed double-digit growth before the Volt PFA launch broadened the opportunity in the U.S.

There is also a longer runway beyond the current headlines. Abbott is focusing on higher-margin areas such as cancer diagnostics and the expanding Libre franchise, while still benefiting from exposure to essential healthcare demand.

Where the market may be overreacting

The market's hardest question is how much weight to give a safety signal against that operating record.

The issue is real, but the panic may be exaggerated. The FDA linked 860 serious injuries and seven deaths to faulty glucose readings from certain FreeStyle Libre 3 and Libre 3 Plus sensors as of early January 2026. For investors, that is enough to trigger worst-case scenarios. For valuation, the key question is whether the issue is likely to change Abbott's long-term cash-flow model permanently, or mainly compress willingness to pay for a period.

Abbott says it has identified and resolved the root cause. If that proves correct, the market may eventually treat the episode as contained rather than systemic. Even so, regulatory and safety headlines can damage confidence for longer than they damage economics.

What would make ABT more than just a cheap stock

Cheap becomes interesting when price has room to move toward earnings power, not just toward a spreadsheet estimate. Abbott is still trading at $112, near the low end of its $105 to $141 52-week range, while the broader valuation picture still points to a discount after the selloff.

The operating backdrop also remains substantial. Abbott still generates about US$22.5b of Medical Devices revenue, and its market capitalization stands at roughly 175.4 B market cap. If sentiment improves without a corresponding hit to earnings, much of the gap between price and value could narrow.

Catalysts and watchpoints

The simplest rerating path is not perfect fundamentals. It is lower perceived risk. If investors stop treating every headline as proof that the earnings model is cracking, sentiment alone could push shares toward more normal valuation levels.

The traps are clear too. If nutrition litigation or glucose-monitoring safety concerns start to affect market share, reimbursement, or margins in a durable way, this stops being a fear-driven discount and starts being a business-quality problem.

The signposts to watch are straightforward:

• whether management's claim that the glucose-reading issue has been contained holds up
• whether Medical Devices keeps growing at a healthy pace
• whether nutrition remains a near-term drag or starts to recover
• whether higher-margin initiatives such as cancer diagnostics keep progressing

If the discount is driven mainly by emotion rather than earnings damage, Abbott may offer more upside than the headline risk suggests. If the operating scaffold slips, the valuation case weakens quickly.